Jeffrey Kindler Sells 106,837 Shares of Precigen (NASDAQ:PGEN) Stock

Key Points

• Jeffrey Kindler, Director of Precigen, Inc., sold 106,837 shares at an average price of $3.38, resulting in a total transaction of approximately $361,109, which marks a 23.59% decrease in his stock position.
• Shares of Precigen have seen a trading volume of over 4.3 million recently, with a current stock price of $3.34, and the company has a market capitalization of $995.22 million.
• Analysts maintain a positive outlook with a consensus rating of "Moderate Buy" and an average price target of $8.25 for Precigen's shares.

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) Director Jeffrey Kindler sold 106,837 shares of Precigen stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $3.38, for a total transaction of $361,109.06. Following the completion of the sale, the director owned 346,070 shares of the company's stock, valued at $1,169,716.60. This represents a 23.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Precigen Price Performance

Shares of NASDAQ:PGEN traded up $0.05 during mid-day trading on Wednesday, hitting $3.34. The company had a trading volume of 4,371,158 shares, compared to its average volume of 4,147,403. The firm has a fifty day moving average price of $3.18 and a 200 day moving average price of $2.09. The company has a market capitalization of $995.22 million, a PE ratio of -7.95 and a beta of 1.82. Precigen, Inc. has a one year low of $0.65 and a one year high of $5.22.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. The business had revenue of $0.86 million during the quarter, compared to the consensus estimate of $0.67 million. Research analysts expect that Precigen, Inc. will post -0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $8.50 price target on shares of Precigen in a research report on Tuesday, August 19th. Citigroup reissued an "outperform" rating on shares of Precigen in a research report on Tuesday, August 19th. Wall Street Zen raised shares of Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. JMP Securities lifted their price target on shares of Precigen from $6.00 to $8.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. raised shares of Precigen from an "underweight" rating to a "neutral" rating in a report on Friday, August 15th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $8.25.

Hedge Funds Weigh In On Precigen

A number of hedge funds and other institutional investors have recently made changes to their positions in PGEN. BNP Paribas Financial Markets purchased a new position in shares of Precigen in the 4th quarter worth about $27,000. Bank of America Corp DE boosted its holdings in shares of Precigen by 11.6% in the 4th quarter. Bank of America Corp DE now owns 207,300 shares of the biotechnology company's stock worth $232,000 after buying an additional 21,626 shares during the last quarter. ProShare Advisors LLC boosted its holdings in shares of Precigen by 26.6% in the 4th quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock worth $58,000 after buying an additional 10,900 shares during the last quarter. Apella Capital LLC purchased a new position in shares of Precigen in the 1st quarter worth about $40,000. Finally, Headlands Technologies LLC purchased a new position in shares of Precigen in the 1st quarter worth about $87,000. 33.51% of the stock is owned by hedge funds and other institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.